Ver vídeos

Your Planner

What is my current Skilarence dose?

Your healthcare professional may change your Skilarence treatment plan depending on how your psoriasis improves and if you experience any side effects. Every time he or she changes your treatment plan, you can write the new plan on a new line.

Your healthcare provider will take regular blood and urine tests to make sure your treatment is not causing problems with your bood, liver or kidneys.

They will also monitor your conditions ir order to assess any changes in your psoriasis. Once you receive your results your doctor can explain anything you are not sure about. Your doctor may change your dose based on your test results and how you feel.

If you have any question about the use of this medicine, ask your doctor or pharmacist.

Report adverse event

This website provides information to guide you during treatment with Skilarence. Please refer to the Patient Information Leaflet contained within your medicine pack for further information.

If you get any side effects, talk to your healthcare professional, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ (for United Kingdom) or by contacting the HPRA (for Ireland) at: Website: www.hpra.ie, e-mail: medsafety@hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine. Adverse events should also be reported to Almirall Ltd. IE Tel: +353 (0)14319836; UK Tel: 0800 0087 399; Email: Almirall@EU.ProPharmaGroup.com

Please read our Drug Safety Privacy Policy where you will find details of how we handle the processing of personal information when dealing with your adverse event report.

This website is intended only for patients taking Skilarence® (dimethyl fumarate) to help them maximise their treatment’s benefits. Please refer to the Patient Information Leaflet contained within the medicine pack for further information.


If you get any side effects, talk to your healthcare professional, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ (for United Kingdom) or by contacting the HPRA (for Ireland) at: Website: www.hpra.ie, e-mail: medsafety@hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.

By reporting side effects you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Almirall Ltd. IE Tel: +353 (0)14319836; UK Tel: 0800 0087 399; Email: Almirall@EU.ProPharmaGroup.com